ZYMVOL and AMINOVERSE team up to develop custom-made alcohol dehydrogenases Read more about ZYMVOL and AMINOVERSE team up to develop custom-made alcohol dehydrogenases
ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021 Read more about ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021
ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry Read more about ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry
VIVEbiotech winner of the 2020 Gipuzkoa SME Award Read more about VIVEbiotech winner of the 2020 Gipuzkoa SME Award
New H2020 project on ATMPs. Asphalion is the regulatory partner of the ARDAT project Read more about New H2020 project on ATMPs. Asphalion is the regulatory partner of the ARDAT project
We’ve been awarded a one million euro grant by the Ministry of Science to study brain tumor biomarkers with Fundación Rioja Salud and the University of the Balearic Islands Read more about We’ve been awarded a one million euro grant by the Ministry of Science to study brain tumor biomarkers with Fundación Rioja Salud and the University of the Balearic Islands
ORYZON to present further positive efficacy data from iadademstat ALICE Phase IIa trial at the 62nd Congress of the American Society of Hematology Read more about ORYZON to present further positive efficacy data from iadademstat ALICE Phase IIa trial at the 62nd Congress of the American Society of Hematology
ORYZON receives approval to start PORTICO Phase IIb trial with vafidemstat in Borderline Personality Disorder Read more about ORYZON receives approval to start PORTICO Phase IIb trial with vafidemstat in Borderline Personality Disorder
Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes Read more about Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes
BHV Partners settles in the Barcelona Science Park and closes a 500,000 euros investment round Read more about BHV Partners settles in the Barcelona Science Park and closes a 500,000 euros investment round
